quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:55:00·126d
PRRelease
ADC Therapeutics SA logo
Crinetics Pharmaceuticals Inc. logo
GT Biopharma Inc. logo
+2

Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines

ADCT· ADC Therapeutics SACRNX· Crinetics Pharmaceuticals Inc.GTBP· GT Biopharma Inc.STRO· Sutro Biopharma Inc.TCRX· TScan Therapeutics Inc.
Health Care
Original source

Companies

  • ADCT
    ADC Therapeutics SA
    Health Care
  • CRNX
    Crinetics Pharmaceuticals Inc.
    Health Care
  • GTBP
    GT Biopharma Inc.
    Health Care
  • STRO
    Sutro Biopharma Inc.
    Health Care
  • TCRX
    TScan Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Apr 7STROUpdateLeerink Partners$38.00
  • Mar 24STROUpdateWells Fargo$27.00
  • Mar 24STROUpdateH.C. Wainwright$28.00
  • Jan 20STROUpdateCitizens JMP$23.00
  • Jan 12CRNXUpdateGoldman$67.00
  • Nov 14TCRXUpdateMorgan Stanley-

Related

  • SEC1d
    SEC Form DEFA14A filed by Sutro Biopharma Inc.
  • SEC1d
    SEC Form DEF 14A filed by Sutro Biopharma Inc.
  • SEC2d
    Amendment: SEC Form SCHEDULE 13G/A filed by Sutro Biopharma Inc.
  • SEC2d
    SEC Form SCHEDULE 13G filed by Sutro Biopharma Inc.
  • SEC4d
    SEC Form DEFA14A filed by ADC Therapeutics SA
  • SEC4d
    SEC Form DEF 14A filed by ADC Therapeutics SA
  • PR4d
    Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026
  • SEC7d
    SEC Form DEF 14A filed by TScan Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022